Expanded access for repotrectinib
Treatments studied
This trial provides access to repotrectinib, a targeted therapy for certain cancers, when no other treatment options are available. It aims to give patients a chance to try this medication under a special program.
Summary written for real people, not researchers, by Clin2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
This trial is a safety follow-up study for people who are already being treated with repotrectinib in Korea. It looks at how well the drug works and what side effects may occur in patients with ROS1-positive lung cancer or NTRK-positive solid tumors.
This trial tests a targeted pill called repotrectinib for people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The drug aims to shrink brain tumors and control the cancer, especially when brain-focused treatments like surgery or radiation are not needed right away.
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.